FDA approves Novo Nordisk’s oral GLP-1 pill for weight loss
The approval expands the Wegovy portfolio beyond injections, providing a new administration option for patients.
The approval expands the Wegovy portfolio beyond injections, providing a new administration option for patients.
The end of enhanced ACA premium support in 2026 will likely push millions off marketplace plans, increasing uninsured visits to safety-net clinics and assistance programs.
Hundred Health aims to address what the company describes as a gap between data access and actionable guidance.
This action bypasses House leadership and ensures a vote as early as January 2026, after the subsidies expire under current law.
From intermittent fasting to GLP-1s, Americans are rethinking how they lose weight—and what "healthy" really looks like.
“People will die,” said Senator Jon Ossoff, Democrat of Georgia.
Recent surveys show that one in three Americans now uses AI for some aspects of personal health management.
“The support from Aetna is instrumental in helping us provide not just shelter, but a pathway to stability and independence for our residents.“
Prices for Wegovy, Ozempic, and Zepbound drop from over $1,000 to $350 with the new deal. Medicare coverage begins for GLP-1 obesity drugs for the first time.
Community Access National Network (CANN) urges lawmakers to prioritize patients over profits in 340B reforms.
A Case Western study indicates the shingles vaccine might provide broader health benefits.
CEO Mark Newman explains how retail pharmacies are becoming central to care delivery and the direct-pay model reshaping health care.
A prolonged government shutdown would result in significant disruptions to health care funding and oversight.
Researchers warn that ending subsidies could threaten community care access and increase financial pressure on providers.
With 84% of employees feeling underappreciated and half ready to leave, experts warn the industry is losing staff faster than it can replace them.